Katy J L Bell
Overview
Explore the profile of Katy J L Bell including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
89
Citations
861
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ackermann D, Bracken K, Hersch J, Janda M, Turner R, Bell K
Contemp Clin Trials Commun
. 2025 Mar;
44:101461.
PMID: 40051673
Background: This scoping review aims to collate and describe data on recruitment, retention, and strategies used to improve these, in randomised controlled trials of melanoma surveillance. Methods: We searched MEDLINE,...
2.
3.
Smith A, Lai B, Zaman S, Wong P, Foo F, Bell K, et al.
Australas J Dermatol
. 2025 Feb;
PMID: 39985232
Background: Psoriasis is a risk factor for cardiovascular disease (CVD). This risk is independent and incremental to traditional cardiovascular (CV) risk factors, but clinician and patient perspectives on this risk...
4.
Lai B, Soyer H, Zhu L, Ferguson P, OBrien B, Dodds T, et al.
JAMA Dermatol
. 2024 Oct;
160(12):1345-1352.
PMID: 39476175
Importance: There is poor accuracy and reproducibility for the histopathologic diagnosis of melanocytic skin lesions, and the provision of clinical information may improve this. Objective: To examine the impact of...
5.
Williams J, Moraga Masson F, McGain F, Stancliffe R, Pilowsky J, Nguyen N, et al.
Intensive Care Med
. 2024 Oct;
50(12):2019-2030.
PMID: 39453490
Purpose: Low-value care is common in intensive care units (ICUs), unnecessarily exposing patients to risks and harms, incuring costs to the patient and healthcare system, and contributing to healthcare's carbon...
6.
Lindsay D, Bell K, Olsen C, Whiteman D, Pathirana T, Collins L
Br J Dermatol
. 2024 Jul;
191(6):906-913.
PMID: 39026390
Background: Research suggests that a high proportion of melanoma in situ (MIS) may be overdiagnosed, potentially contributing to overtreatment, patient harm and inflated costs for individuals and healthcare systems. However,...
7.
Medcalf E, Turner R, Espinoza D, He V, Bell K
Contemp Clin Trials
. 2024 Jun;
143:107602.
PMID: 38857674
Background: Missing outcome data is common in trials, and robust methods to address this are needed. Most trial reports currently use methods applicable under a missing completely at random assumption...
8.
Horvath A, Bell K, Ceriotti F, Jones G, Loh T, Lord S, et al.
Clin Chem Lab Med
. 2024 Jun;
62(8):1474-1482.
PMID: 38836433
Analytical performance specifications (APS) based on outcomes refer to how 'good' the analytical performance of a test needs to be to do more good than harm to the patient. Analytical...
9.
Jones G, Bell K, Ceriotti F, Loh T, Lord S, Sandberg S, et al.
Clin Chem Lab Med
. 2024 May;
62(8):1531-1537.
PMID: 38801089
Analytical performance specifications (APS) are used for decisions about the required analytical quality of pathology tests to meet clinical needs. The Milan models, based on clinical outcome, biological variation, or...
10.
Li H, Kalra M, Zhu L, Ackermann D, Taba M, Bonner C, et al.
Med Decis Making
. 2024 Apr;
44(4):437-450.
PMID: 38651834
Objective: To investigate the potential impacts of optimizing coronavirus disease 2019 (COVID-19) rapid antigen test (RAT) self-testing diagnostic accuracy information. Design: Online randomized experiment using hypothetical scenarios: in scenarios 1...